UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

FGFR a promising druggable target in cancer: molecular biology and new drugs

Critical reviews in oncology/hematology, 2017-05, Vol.113, p.256-267

2017

Link zum Volltext

Verfügbarkeit prüfen

The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells

Cancers, 2020-04, Vol.12 (5), p.1091

2020

Link zum Volltext

Verfügbarkeit prüfen

Resistance Mechanisms to AZD9291 and Rociletinib-Letter

Clinical cancer research, 2017-07, Vol.23 (14), p.3966-3966

2017

Link zum Volltext

Verfügbarkeit prüfen

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

Cancers, 2015-03, Vol.7 (2), p.556-573

2015

Link zum Volltext

Verfügbarkeit prüfen

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

OncoTargets and therapy, 2016-01, Vol.9, p.6065-6074

2016

Link zum Volltext

Verfügbarkeit prüfen

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells

American journal of cancer research, 2017-01, Vol.7 (4), p.816-830

2017

Link zum Volltext

Verfügbarkeit prüfen

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

World journal of clinical oncology, 2016-12, Vol.7 (6), p.425-432

2016

Link zum Volltext

Verfügbarkeit prüfen

Onartuzumab in lung cancer: the fall of Icarus?

Expert review of anticancer therapy, 2015-05, Vol.15 (5), p.487-489

2015

Link zum Volltext

Verfügbarkeit prüfen

APR-246 (PRIMA-1MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

Cancer letters, 2016-06, Vol.375 (2), p.313-322

2016

Link zum Volltext

Verfügbarkeit prüfen

cMET Exon 14 Skipping: From the Structure to the Clinic

Journal of thoracic oncology, 2016-09, Vol.11 (9), p.1423-1432

2016

Link zum Volltext

Verfügbarkeit prüfen

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

Biochemical pharmacology, 2019-08, Vol.166, p.128-138

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1074: Combining forces: Synergy of erlotinib and crizotinib in a wild-type squamous non-small cell lung cancer cell line

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1074-1074

2017

Link zum Volltext

Verfügbarkeit prüfen

The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20043-e20043

2017

Link zum Volltext

Verfügbarkeit prüfen

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Journal of visualized experiments, 2016-05 (111)

2016

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Journal of cellular physiology, 2020-11, Vol.235 (11), p.8085-8097

2020

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?

Journal of clinical oncology, 2017-02, Vol.35 (6), p.692-693

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2593: Combination therapy with EGFR-TKI and cMET-TKIs in non-small cell lung cancer: the golden duo

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2593-2593

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2242: cMET in non-small cell lung cancer: pieces of the puzzle

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2242-2242

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?: Track: Biology and Pathogenesis

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S219-S220

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S219-S220

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.09: cMET in NSCLC: Expression, Amplification and Mutations

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S221-S222

2016

Link zum Volltext

Verfügbarkeit prüfen

Deep sequencing of the TP53 gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of TP53 variants

Tumor biology, 2017-02, Vol.39 (2), p.1010428317694327-1010428317694327

2017

Link zum Volltext

Verfügbarkeit prüfen

P2.09: cMET in NSCLC: Expression, Amplification and Mutations: Track: Biology and Pathogenesis

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S221-S222

2016

Link zum Volltext

Verfügbarkeit prüfen

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

Molecules (Basel, Switzerland), 2019-12, Vol.24 (24), p.4443

2019

Link zum Volltext

Verfügbarkeit prüfen

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN

Oncotarget, 2017-08, Vol.8 (32), p.53068-53083

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Humans
(26)
Palliative Care
(18)
Nursing Homes
(17)
Oncology
(14)
Aged
(12)
Female
(11)
Health Care Sciences & Services
(11)
Male
(10)
End-Of-Life Care
(9)
General & Internal Medicine
(8)
Medicine, General & Internal
(8)
Carcinoma, Non-Small-Cell Lung - Genetics
(7)
Dementia
(7)
Europe
(7)
Long Term Care
(7)
Mutation
(7)
Nsclc
(7)
Aged, 80 And Over
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

FGFR a promising druggable target in cancer: molecular biology and new drugs

The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells

Resistance Mechanisms to AZD9291 and Rociletinib-Letter

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Onartuzumab in lung cancer: the fall of Icarus?

APR-246 (PRIMA-1MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

cMET Exon 14 Skipping: From the Structure to the Clinic

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

Abstract 1074: Combining forces: Synergy of erlotinib and crizotinib in a wild-type squamous non-small cell lung cancer cell line

The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?

Abstract 2593: Combination therapy with EGFR-TKI and cMET-TKIs in non-small cell lung cancer: the golden duo

Abstract 2242: cMET in non-small cell lung cancer: pieces of the puzzle

P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?: Track: Biology and Pathogenesis

P2.06: Exosomal miRNA Analysis in Non-Small Cell Lung Cancer: New Liquid Biomarker?

P2.09: cMET in NSCLC: Expression, Amplification and Mutations

Deep sequencing of the TP53 gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of TP53 variants

P2.09: cMET in NSCLC: Expression, Amplification and Mutations: Track: Biology and Pathogenesis

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN

Suchergebnisse filtern